- Open Access
Proteomics computational analyses suggest that the bornavirus glycoprotein is a class III viral fusion protein (γ penetrene)
© Garry and Garry; licensee BioMed Central Ltd. 2009
- Received: 13 August 2009
- Accepted: 18 September 2009
- Published: 18 September 2009
Borna disease virus (BDV) is the type member of the Bornaviridae, a family of viruses that induce often fatal neurological diseases in horses, sheep and other animals, and have been proposed to have roles in certain psychiatric diseases of humans. The BDV glycoprotein (G) is an extensively glycosylated protein that migrates with an apparent molecular mass of 84,000 to 94,000 kilodaltons (kDa). BDV G is post-translationally cleaved by the cellular subtilisin-like protease furin into two subunits, a 41 kDa amino terminal protein GP1 and a 43 kDa carboxyl terminal protein GP2.
Class III viral fusion proteins (VFP) encoded by members of the Rhabdoviridae, Herpesviridae and Baculoviridae have an internal fusion domain comprised of beta sheets, other beta sheet domains, an extended alpha helical domain, a membrane proximal stem domain and a carboxyl terminal anchor. Proteomics computational analyses suggest that the structural/functional motifs that characterize class III VFP are located collinearly in BDV G. Structural models were established for BDV G based on the post-fusion structure of a prototypic class III VFP, vesicular stomatitis virus glycoprotein (VSV G).
These results suggest that G encoded by members of the Bornavirdae are class III VFPs (gamma-penetrenes).
- Infectious Hematopoietic Necrosis Virus
- Fusion Domain
- Fusion Loop
- Vesicular Stomatitis Virus Glycoprotein
- Bovine Ephemeral Fever Virus
Members of the Bornaviridae are enveloped with nonsegmented negative-stranded RNA genomes. The type member is Borna disease virus (BDV), the causative agent of Borna disease, an often fatal neurological disease occurring mainly in horses and sheep in endemic regions of central Europe. The natural host range, prevalence, and geographic distribution of BDV are broad . For example, recent studies demonstrated the existence of an avian reservoir of diverse bornaviruses  and provided evidence that bornaviruses are the etiologic agent for proventricular dilatation disease, a neuroinflammatory disease of psittacine birds . It is yet to be established whether bornaviruses causes any overt disease in humans. However, correlative evidence exists linking BDV infection with neuropsychiatric disorders, such as bipolar disorder [4, 5].
BDV is noncytolytic and highly neurotropic . Although viral RNA and proteins are readily detectable in BDV-infected cells, production of cell-free virions or cell-associated infectivity is absent or extremely low . BDV propagates via cell-to-cell spread within the central nervous system and cultured cells in the absence of detectable assembled virions [8, 9]. It is likely that BDV initially interacts with the plasma membrane, followed by endocytosis and penetration by membrane fusion; cell-to-cell spread of bornaviruses may involve distinct mechanisms . The BDV genome contains at least six open reading frames (ORF), and the product of BDV ORF IV corresponds to the type I surface glycoproteins found in other viruses of the order Mononegavirales. The BDV glycoprotein (G, GP-C, gp84) migrates due to extensive glycosylation with an apparent molecular mass of 84,000 to 94,000 kilodaltons (kDa). BDV G is post-translationally cleaved by the cellular subtilisin-like protease furin [11, 10]. The amino terminal product (GP1, Gn, gp41) has an apparent molecular mass of 41 kDa. GP1 was initially difficult to detect in infected cells or virions due to its high glycan content, which shields antigenic sites from antibodies. However, a peptide-generated antibody was used to demonstrate the presence of GP1 in virions and infected cells . The carboxyl terminal product, molecular mass 43 kDa (GP2, Gc, gp43), is less heavily glycosylated and readily detected in infected cells and virions. The uncleaved product G accumulates in the endoplasmic reticulum and perinuclear region. G is not detected on the plasma membrane, whereas GP2, but not GP1, accumulates at the cell surface . There are conflicting results as to the presence of uncleaved G in virions [13, 9]. GP2 contains several hydrophobic sequences, and appears capable of mediating cell:cell fusion in the absence of other BDV surface proteins [10, 14]. GP1 linked to the vesicular stomatitis virus glycoprotein transmembrane domain (VSV G TM) domain is sufficient, in the absence of GP2, for receptor recognition, cell fusion and entry .
The structures of the bornavirus glycoproteins have not been determined, and it is unknown whether or not these proteins belong to any of the three known classes of proteins that mediate membrane fusion and entry of enveloped viruses. Orthomyxoviruses (excepting members of the Thogotovirus genus, which are insect pathogens), retroviruses, paramyxoviruses, filoviruses, arenaviruses, and coronaviruses encode class I viral fusion proteins (VFP, aka class I or α-penetrenes). Class I VFP contain a "fusion peptide," a cluster of hydrophobic and aromatic amino acids located at or near the amino terminus that initially interacts with the target cell membrane (plasma membrane or vesicle membrane) [16–23]. Most class I VFP have an aromatic amino acid (aa) rich pre-membrane domain, while all have a carboxyl terminal anchor. The post-fusion forms of class I viral fusion proteins have an extended amino terminal helix (N-helix, HR1), and a carboxyl terminal helix (C-helix, HR2) or "leash domain" that mediate trimerization.
Members of the Flavivirus genus of the Flaviviridae and the Alphavirus genus of the Togaviridae encode class II viral fusion proteins (class II or β-penetrenes) possessing three domains (I-III) of mostly antiparallel β-sheets, a membrane proximal α-helical stem domain and a carboxyl terminal anchor [24–26]. The fusion loops of class II VFP are internal and located in domain II, the fusion domain. Hepaciviruses and Pestiviruses, the two other genuses in the Flaviviridae, appear to encode truncated class II VFP . Proteomics computational analyses and other studies suggest that the carboxyl terminal glycoproteins (Gc) of bunyaviruses, tenuiviruses and Caenorhabditis elegans retroviruses, are class II VFP [28, 29].
The third class of VFP (class III or γ-penetrenes) is represented by glycoprotein (G) of rhabdoviruses and glycoprotein B (gB) of herpesviruses. Class III VFP contain a fusion domain, which is similar structurally to the fusion domains of class II VFP, other β-sheet domains, an extended α-helical domain in the post-fusion form, a membrane proximal stem and a carboxyl terminal anchor [30–32]. The extended α-helices in the post-fusion forms of rhabdovirus G and herpesvirus gB are involved in trimerization, a similar function served by the long α-helices in the post-fusion structures of class I VFP. Our prior proteomics computational analyses suggested that the fusion proteins of group I nucleopolyhedroviruses (NPV) of the Baculoviridae and members of the Thogotovirus genus of the Orthomyxoviridae, which together form the GP64 superfamily, are also class III VFP . A recent X-ray crystallographic study, published after our prior manuscript, confirmed that GP64 superfamily members are class III VFP . Here, proteomics computational analyses are presented suggesting that bornavirus G are class III VFP.
Sequence and structural comparisons were performed for Borna disease virus strain V glycoprotein isolated from a horse (accession number NP042023). Additional bornavirus G sequences used in the analyses included ABH03174, CAC70658 (horse), AAL49985 (sheep), ABH03169 (rabbit), ACG59352 (avian - Aratinga solstitialis), and AAA91195 (human). We also made comparisons of bornavirus G with Thogato virus strain SiAr 126 envelope glycoprotein precursor (P28977), the Autographa california multiple nucleopolyhedrovirus GP64 superfamily protein (P17501) and other GP64 superfamily members. Representatives of G from six genera of the Rhabdoviridae were also used for sequence and structural comparisons: Vesiculovirus: VSV strain Indiana (AAA48370); Lyssavirus: rabiesvirus strain street (AAA47211); Ephemerovirus: bovine ephemeral fever virus structural G (P32595) and nonstructural G(P32596); Novirhabdovirus: infectious hematopoietic necrosis virus (CAA61498); Cytorhabdovirus: lettuce necrosis yellows virus glycoprotein (LYP425091); Nucleorhabdovirus: rice yellow stunt virus (AB011257) and an unclassified rhabdovirus: Taastrup virus (AY423355). We also compared bornavirus G to VFP of representative members of the Herpesviridae, Flaviviridae, Togaviridae, and Bunyaviridae.
Proteomics computational methods
Methods developed by William Gallaher and coworkers to derive models of VFP have been described previously [22, 18, 17, 20]. William Pearson's LALIGN program http://www.ch.embnet.org/software/LALIGN_form.html, which implements a linear-space local similarity algorithm  was used to perform regional alignments. PHD (Columbia University Bioinformatics Center, http://cubic.bioc.columbia.edu/predictprotein/), which is part of the ProteinPredict suite was the preferred method of secondary structure prediction . Domains with significant propensity to form transmembrane helices were identified with TMpred (ExPASy, Swiss Institute of Bioinformatics, http://www.ch.embnet.org/software/TMPRED_form.html). TMpred is based on a statistical analysis of TMbase, a database of naturally occurring transmembrane glycoproteins . Sequences with propensity to interface with a lipid bilayer were identified with Membrane Protein eX plorer version 3.0 from the Stephen White laboratory using default settings , which can be used to calculate scores on the Wimley-White interfacial hydrophobicity scale (WWIHS) . Figures were drawn using Freehand (Macromedia).
Similar sequences and common structural/functional motifs are located collinearly in VSV and BDV G
Another domain identifiable with computational tools in BVD G is the carboxyl terminal transmembrane anchor. TMpred, an algorithm that identifies possible transmembrane helices, assigns a significant score (2578, >500 is statistically significant) to BVD G aa 468-493, which suggests that this sequence includes the transmembrane anchor (violet cones). Two other potential TM segments are present in BDV G (274-294 and 303-327). However, it is not likely that these regions are embedded in the membrane, either in G or GP2 because of the likely dicysteine bonding between cysteines 272 and 317 or other potential linkages involving cysteine 317. PHD analyses also predict the presence of an α-helical stem domain with several aromatic aa prior to the transmembrane anchor (aa 445-474), a feature present in both class II and III VFP [41, 42]. Therefore, we have designated the sequence 475-493 as the transmembrane anchor, recognizing that the stem domain, which contains several aromatic amino acids, is likely to interface with the viral membrane.
The fusion domains (referred to here as domain II) of all class II or III VFP contain 1 or 2 fusion loops, which give significant scores on the WWIHS . Sequences with positive WWIHS have a high potential to interface with or disrupt lipid membranes, and therefore are key features of VFP. Another feature of the fusion domains of class II and III VFP is the presence of several dicysteine bonds, which stabilize the overall domain architecture. A region in bornavirus G (BVD aa 66-183) with 12 cysteine residues, plus 2 sequences with positive WWIHS scores (Fig. 1, red, 74-102, 119-155) is likely to represent the fusion domain of BDV G.
BDV G is more heavily glycosylated than VSV G, THOV G or baculovirus GP64, It is also more heavily glycosylated than gB of HSV-1 (Fig. 2). Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) gB are closely related in sequence to HSV-1 gB. Recent studies confirm that EBV gB is a class II VFP , and it is likely that all herpesvirus gB are class II VFP. CMV gB is glycosylated to a similar extent as BDV G, while EBV gB has an intermediate level of glycosylation. Therefore, a high level of glycosylation does not preclude the possibility that BDV G is a class III VFP.
BDV G and other bornavirus G have consensus furin cleavage sites (RRRR) prior to the extended α helix (Fig. 1, 2) that are utilized in infected cells to cleave the proteins into two subunits GP1 and GP2 [11, 9]. Several alphaherpesviruses, such as varicella zoster virus (VZV), posses a furin cleavage site in the analogous location (Fig. 2 dashed orange arrow). Most beta and gamma-herpesviruses, including CMV and EBV, have a furin cleavage site prior to the extended α-helix. Therefore, possession of a furin cleavage site does not preclude the possibility that BDV GP is a class III VFP.
The BDV G structural model presented here is not intended as a definitive structural prediction. Rather, there are many possible alternatives to the secondary and tertiary structures and the cysteine linkages of BDV G. For example, it is possible that in a minor subset of G may be cross-linked via cysteine binding such that the GP1 and 2 subunits are covalently bound. The modeling does establish that feasible structures exist that are consistent with the secondary structure predictions and with the assignment of BDV G as a class III VFP.
Proteomics computational analyses suggest that bornavirus G are class III VFP. Computational analyses and other methods predict that each of the major features common to class III fusion proteins are present in BVD G, including internal fusion loops, an extended α helical domain, a stem domain and a carboxyl terminal transmembrane domain. These features of BDV G are located collinearly with those of VSV G, a prototypic class III VFP [30, 31]. On the basis of sequence similarities amongst G of members of the Bornaviridae it is likely that all are class III VFP. Structural models including feasible cysteine linkage maps could be readily established for BDV G using the VSV G post-fusion structure as a scaffold. The fusion domains of BVD G, which we refer to here in a unified domain nomenclature as domain II, appear to be stabilized by cysteine bonds and to contain one or more loops with positive WWIHS scores, features characteristic of the fusion domains of both class II and III VFP. Differences between VSV and BDV G include the presence of a consensus furin cleavage site and a higher number of N-glycosylation sites in BDV G. However, many herpesvirus gB, which are class III VFP, contain a furin cleavage domain prior to the extended α helix in domain III and are more heavily glycosylated than VSV G. Therefore, the presence of the furin cleavage site and high glycan content in BDV G does not preclude its putative inclusion in class III. Whether or not the secondary and tertiary folding of BDV GP conforms to the domain structure of class III VFP will require x-ray crystallographic or other physical structural determinations.
The three VFP classes for enveloped virus membrane glycoproteins were established based on structural similarities in the post-fusion configurations. Therefore, it is likely that there is a common post-fusion (low pH) configuration of class III VFP, and that BDV G has a post-fusion structure similar to VSV G. In contrast, the prefusion configurations of class I, II and II VFPs are highly variable. The virion configuration of VSV G is homotrimer arranged in a tripod shape with the fusion domains corresponding to the legs of the tripod . No structural prediction of the prefusion configurations of BVD GP is possible.
As in the case of class I fusion proteins, BDV G is cleaved by a cellular protease into two subunits [11, 9]. It has been suggested that hydrophobic sequences following this cleavage site near the GP2 N terminus may function as a fusion peptide . The current modeling suggests that bornavirus G is not a class I VFP, and does not corroborate the existence of a "fusion peptide" in GP2. The position of predicted α helices, dicysteine linkages and membrane interactive regions (sequences with positive WWIHS scores) are not consistent with assignment of BDV G to class I. However, the concept that multiple domains of bornavirus G participate in fusion of viral and cellular membranes is consistent with current viral entry models. In class I VFP both the amino terminal fusion peptide, the pre-membrane aromatic domain and the TM cooperate to mediate lipid mixing. Likewise, in class II and III VFP, fusion loops in domain II, the stem domain, TM and other WWIHS score positive sequences all appear to participate in fusion. Several of the domains of GP1 and GP2, particularly the putative fusion loops (domain II), the sequences with positive WWIHS scores in GP2, and the stem and TM domain could cooperate or interact to mediate fusion and entry of BDV.
BDV entry is via clathrin-mediated endocytosis, and the fusion between viral and cellular membranes occurs in the mildly acidic environment of the early endosome . The domains of BDV G involved in receptor recognition and cell entry have not been defined. GP1 sequences are capable of mediating attachment and entry in VSV pseudoparticles in the absence of GP2 . BDV-infected cells exhibit syncytium formation upon exposure to low-pH medium . This pH-dependent cell fusion event is likely mediated by GP2 since it is the only membrane-anchored BDV glycoprotein found on the plasma membrane. These results suggest that both GP1 and GP2 are involved in membrane fusion, either cooperatively or in the case of cell surface expressed GP2 independently. An analogous situation may exist for hepatitis C virus (HCV). Our previous modeling suggested that the envelope proteins of HCV split the duties performed by envelope proteins of other members of the Flaviviridae, E of flaviviruses and E2 of pestiviruses . HCV E1 contains the fusion loops that are analogous to the domain II fusion loops of E/E2, while HCV E2 contains receptor binding domains analogous to domain III of E/E2, as well as the stem domain.
The BDV cellular receptor(s) has not been identified. Baculoviruses, which have a broad host range, may not possess a specific protein receptor. Rather, it has been suggested that the fusion loops (domain II) of baculovirus gp64, a class III VFP, may be the initial binding point with lipids of the target cell membrane . The host range of bornaviruses also appears to be broad. Whether bornavirus G utilizes a specific protein receptor or bind to lipids or other ubiquitous components of cellular membranes remains to be determined.
Orthomyxoviridae, Retroviridae, Paramyxoviridae, Filoviridae, Arenaviridae, and Coronaviridae and Baculoviridae have members that encode class I VFP [16, 22, 17–21, 45]. Flaviviridae, Togaviridae, and Bunyaviridae family members are known or appear to have members that encode class II VFP [24, 27–29]. If the current analyses are correct, BDV G joins rhabdovirus G, herpeviruses gB, thogotovirus G and baculovirus GP64 and as a class III VFP. While convergence to common structures is possible, VFP of enveloped viruses may have evolved from a limited number of common progenitors. Support for this hypothesis comes from the remarkable similarities in the post-fusion structures of the VFP in each class, even though the proteins differ dramatically in aa sequence. While, it is probable that other classes of VFP exist, there appears be a limited number of effective structures for virus-mediated membrane fusion.
In the absence of determinations by X-ray crystallography, structural models such as the one proposed here can provide useful hypotheses to guide experimental strategies for development of vaccines or drugs to prevent or treat infection by bornavirus infections. Prior to the availability of X-ray structural data, several potent HIV-1 entry inhibitors were developed [46, 47] based on the Gallaher HIV-1 TM fusion protein model . Fuzeon™ (DP178; T20 enfuvirtide), one of these peptides corresponding to a portion of the carboxyl terminal helix and the pre-anchor domain in this class I VFP, has been shown to substantially reduce HIV-1 load in AIDS patients, and is well-established in the treatment of HIV infection in the United States and European Union . Peptide entry inhibitors of viruses with class II VFP have also been developed , and have also been described for the class III VFP of herpesviruses (Melnik et al., in preparation). Given that bornaviruses cause a range of infectious neurological syndromes in warm-blooded animals, with high mortality rates, veterinary applications of bornavirus entry inhibitors, should be investigated. Confirmation of the still controversial proposal that bornaviruses cause neuropsyciatric disorders in humans would provide additional strong incentives to develop preventative vaccines or therapeutics.
This research was supported by grants DK070551, UC1AI067188, R41AI068230 and R56 AI64617 from the National Institutes of Health and RC-0013-07 from the Louisiana Board of Regents. William R. Gallaher developed the strategy for predicting structures of viral VFPs (and coined this name penetrene). We thank Dr. Gallaher, and Drs. William C. Wimley, Thomas G. Voss, Scott F. Michael, Srikant Dash, Joshua M. Costin, Yancey M. Hrobowski, Ramesh Prabhu, and Michael D. Charbonnet Russell B. Wilson for informative ongoing discussions on viral VFP.
- Ludwig H: The biology of bornavirus. APMIS Suppl 2008, (124):14-20. 10.1111/j.1600-0463.2008.000m2.xGoogle Scholar
- Kistler AL, Gancz A, Clubb S, Skewes-Cox P, Fischer K, Sorber K, Chiu CY, Lublin A, Mechani S, Farnoushi Y, et al.: Recovery of divergent avian bornaviruses from cases of proventricular dilatation disease: identification of a candidate etiologic agent. Virol J 2008, 5: 88. 10.1186/1743-422X-5-88PubMed CentralView ArticlePubMedGoogle Scholar
- Gancz AY, Kistler AL, Greninger AL, Farnoushi Y, Mechani S, Perl S, Berkowitz A, Perez N, Clubb S, DeRisi JL, et al.: Experimental induction of proventricular dilatation disease in cockatiels (Nymphicus hollandicus) inoculated with brain homogenates containing avian bornavirus 4. Virol J 2009, 6: 100. 10.1186/1743-422X-6-100PubMed CentralView ArticlePubMedGoogle Scholar
- Lipkin WI, Schneemann A, Solbrig MV: Borna disease virus: implications for human neuropsychiatric illness. Trends Microbiol 1995,3(2):64-69. 10.1016/S0966-842X(00)88877-0View ArticlePubMedGoogle Scholar
- Dietrich DE, Bode L: Human Borna disease virus-infection and its therapy in affective disorders. APMIS Suppl 2008, (124):61-65. 10.1111/j.1600-0463.2008.00m10.xGoogle Scholar
- Briese T, Lipkin WI, de la Torre JC: Molecular biology of Borna disease virus. Curr Top Microbiol Immunol 1995, 190: 1-16.PubMedGoogle Scholar
- de la Torre JC: Molecular biology of Borna disease virus and persistence. Front Biosci 2002, 7: d569-579. 10.2741/torreView ArticlePubMedGoogle Scholar
- Carbone KM, Duchala CS, Griffin JW, Kincaid AL, Narayan O: Pathogenesis of Borna disease in rats: evidence that intra-axonal spread is the major route for virus dissemination and the determinant for disease incubation. J Virol 1987,61(11):3431-3440.PubMed CentralPubMedGoogle Scholar
- Clemente R, de la Torre JC: Cell-to-cell spread of Borna disease virus proceeds in the absence of the virus primary receptor and furin-mediated processing of the virus surface glycoprotein. J Virol 2007,81(11):5968-5977. 10.1128/JVI.02426-06PubMed CentralView ArticlePubMedGoogle Scholar
- Gonzalez-Dunia D, Cubitt B, de la Torre JC: Mechanism of Borna disease virus entry into cells. J Virol 1998,72(1):783-788.PubMed CentralPubMedGoogle Scholar
- Richt JA, Furbringer T, Koch A, Pfeuffer I, Herden C, Bause-Niedrig I, Garten W: Processing of the Borna disease virus glycoprotein gp94 by the subtilisin-like endoprotease furin. J Virol 1998,72(5):4528-4533.PubMed CentralPubMedGoogle Scholar
- Kiermayer S, Kraus I, Richt JA, Garten W, Eickmann M: Identification of the amino terminal subunit of the glycoprotein of Borna disease virus. FEBS Lett 2002,531(2):255-258. 10.1016/S0014-5793(02)03513-5View ArticlePubMedGoogle Scholar
- Eickmann M, Kiermayer S, Kraus I, Gossl M, Richt JA, Garten W: Maturation of Borna disease virus glycoprotein. FEBS Lett 2005,579(21):4751-4756. 10.1016/j.febslet.2005.07.052View ArticlePubMedGoogle Scholar
- Furrer E, Planz O, Stitz L: Inhibition of Borna disease virus-mediated cell fusion by monoclonal antibodies directed against the viral glycoprotein. Intervirology 2004,47(2):108-113. 10.1159/000077834View ArticlePubMedGoogle Scholar
- Perez M, Watanabe M, Whitt MA, de la Torre JC: N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entry. J Virol 2001,75(15):7078-7085. 10.1128/JVI.75.15.7078-7085.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Wilson IA, Skehel JJ, Wiley DC: Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981,289(5796):366-373. 10.1038/289366a0View ArticlePubMedGoogle Scholar
- Gallaher WR, Ball JM, Garry RF, Griffin MC, Montelaro RC: A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1989,5(4):431-440. 10.1089/aid.1989.5.431View ArticlePubMedGoogle Scholar
- Gallaher WR: Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses. Cell 1996,85(4):477-478. 10.1016/S0092-8674(00)81248-9View ArticlePubMedGoogle Scholar
- Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997,387(6631):426-430. 10.1038/387426a0View ArticlePubMedGoogle Scholar
- Gallaher WR, DiSimone C, Buchmeier MJ: The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol 2001, 1: 1. 10.1186/1471-2180-1-1PubMed CentralView ArticlePubMedGoogle Scholar
- Gallaher W, Garry R: Model of the pre-insertion region of the spike (S2) fusion glycoprotein of the human SARS coronavirus: Implications for antiviral therapeutics.2003. [http://www.virology.net/Articles/sars/s2model.html]Google Scholar
- Gallaher WR: Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987,50(3):327-328. 10.1016/0092-8674(87)90485-5View ArticlePubMedGoogle Scholar
- Sainz B Jr, Rausch JM, Gallaher WR, Garry RF, Wimley WC: Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J Virol 2005,79(11):7195-7206. 10.1128/JVI.79.11.7195-7206.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC: The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 1995,375(6529):291-298. 10.1038/375291a0View ArticlePubMedGoogle Scholar
- Modis Y, Ogata S, Clements D, Harrison SC: Structure of the dengue virus envelope protein after membrane fusion. Nature 2004,427(6972):313-319. 10.1038/nature02165View ArticlePubMedGoogle Scholar
- Gibbons DL, Vaney MC, Roussel A, Vigouroux A, Reilly B, Lepault J, Kielian M, Rey FA: Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus. Nature 2004,427(6972):320-325. 10.1038/nature02239View ArticlePubMedGoogle Scholar
- Garry RF, Dash S: Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology 2003,307(2):255-265. 10.1016/S0042-6822(02)00065-XView ArticlePubMedGoogle Scholar
- Garry CE, Garry RF: Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion proteins (beta-penetrenes). Theor Biol Med Model 2004,1(1):10. 10.1186/1742-4682-1-10PubMed CentralView ArticlePubMedGoogle Scholar
- Plassmeyer ML, Soldan SS, Stachelek KM, Martin-Garcia J, Gonzalez-Scarano F: California serogroup Gc (G1) glycoprotein is the principal determinant of pH-dependent cell fusion and entry. Virology 2005,338(1):121-132. 10.1016/j.virol.2005.04.026View ArticlePubMedGoogle Scholar
- Roche S, Bressanelli S, Rey FA, Gaudin Y: Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science 2006,313(5784):187-191. 10.1126/science.1127683View ArticlePubMedGoogle Scholar
- Roche S, Rey FA, Gaudin Y, Bressanelli S: Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 2007,315(5813):843-848. 10.1126/science.1135710View ArticlePubMedGoogle Scholar
- Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC: Crystal structure of glycoprotein B from herpes simplex virus 1. Science 2006,313(5784):217-220. 10.1126/science.1126548View ArticlePubMedGoogle Scholar
- Garry CE, Garry RF: Proteomics computational analyses suggest that baculovirus GP64 superfamily proteins are class III penetrenes. Virol J 2008, 5: 28. 10.1186/1743-422X-5-28PubMed CentralView ArticlePubMedGoogle Scholar
- Kadlec J, Loureiro S, Abrescia NG, Stuart DI, Jones IM: The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines. Nat Struct Mol Biol 2008,15(10):1024-1030. 10.1038/nsmb.1484View ArticlePubMedGoogle Scholar
- Huang X, Miller W: A time-efficient, linear-space local similarity algorithm. Adv Appl Math 1991, 12: 337-357. 10.1016/0196-8858(91)90017-DView ArticleGoogle Scholar
- Rost B: Prediction in 1D: secondary structure, membrane helices, and accessibility. Methods Biochem Anal 2003, 44: 559-587. full_textPubMedGoogle Scholar
- Hofman K, Stoffel W: TMBASE - A database of membrane spanning protein segments. Bological Chemistry Hoppe-Seyler 1993, 374: 166.Google Scholar
- White S, Snider C, Myers M, Jaysinghe S, Kim J: Membrane Protein Explorer version 3.0.2006. [http://blanco.biomol.uci.edu/mpex/]Google Scholar
- Wimley WC, White SH: Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nat Struct Biol 1996,3(10):842-848. 10.1038/nsb1096-842View ArticlePubMedGoogle Scholar
- Bosch BJ, Zee R, de Haan CA, Rottier PJ: The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 2003,77(16):8801-8811. 10.1128/JVI.77.16.8801-8811.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Allison SL, Stiasny K, Stadler K, Mandl CW, Heinz FX: Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J Virol 1999,73(7):5605-5612.PubMed CentralPubMedGoogle Scholar
- Drummer HE, Boo I, Poumbourios P: Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1. J Gen Virol 2007,88(Pt 4):1144-1148. 10.1099/vir.0.82567-0View ArticlePubMedGoogle Scholar
- Backovic M, Longnecker R, Jardetzky TS: Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci USA 2009,106(8):2880-2885. 10.1073/pnas.0810530106PubMed CentralView ArticlePubMedGoogle Scholar
- Clemente R, de la Torre JC: Cell entry of Borna Disease Virus follows a clathrin mediated endocytosis pathway that requires Rab5 and microtubules. J Virol 2009, in press.Google Scholar
- Eschli B, Quirin K, Wepf A, Weber J, Zinkernagel R, Hengartner H: Identification of an N-Terminal Trimeric Coiled-Coil Core within Arenavirus Glycoprotein 2 Permits Assignment to Class I Viral Fusion Proteins. J Virol 2006,80(12):5897-5907. 10.1128/JVI.00008-06PubMed CentralView ArticlePubMedGoogle Scholar
- Qureshi NM, Coy DH, Garry RF, Henderson LA: Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. Aids 1990,4(6):553-558. 10.1097/00002030-199006000-00009View ArticlePubMedGoogle Scholar
- Wild C, Oas T, McDanal C, Bolognesi D, Matthews T: A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 1992,89(21):10537-10541. 10.1073/pnas.89.21.10537PubMed CentralView ArticlePubMedGoogle Scholar
- Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998,4(11):1302-1307. 10.1038/3293View ArticlePubMedGoogle Scholar
- Hrobowski YM, Garry RF, Michael SF: Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2005, 2: 49. 10.1186/1743-422X-2-49PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.